Log In
BCIQ
Print this Print this
 

Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)

  Manage Alerts
Collapse Summary Pipeline Information
 Pipeline Summary for Products Targeting Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)

BCIQ
Print ChartPrint this
Marketed, 1 Phase III, 1 Phase III, 1 Phase II, 1 Phase II, 1 Phase II, 1 Phase II, 1 Phase II, 1 Phase I/II, 1 Phase I, 2 Phase I, 1 Phase I, 1 Phase I, 1 Phase I, 1 Phase I, 1 Preclinical, 1 Preclinical, 1 Preclinical, 1
Phase of DevelopmentPreclinicalPhase IPhase I/IIPhase IIPhase IIIMarketed
Autoimmune

1

-

-

-

1

1

Cancer

-

1

1

-

-

-

Cardiovascular

-

1

-

1

-

-

Dermatology

-

-

-

1

-

-

Endocrine / Metabolic

-

1

-

1

-

-

Hematology

-

1

-

-

-

-

Inflammation

-

-

-

1

-

-

Neurology

1

1

-

-

-

-

Ophthalmic

-

-

-

1

-

-

Renal

1

2

-

-

1

-




 Products Targeting Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Summary
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

5

$1,961.0M

$620.0M

$350.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury Trial today